Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin’s Lymphomas (NHL) that develops from mature T-cells. PTCL comprises about 10-15% of all NHL cases in United States.
The Peripheral T cell lymphomas was classified by WHO in 2008 and updated in 2016. According to this, the peripheral T cell lymphomas can be broadly classified according to the site of origin of the malignant T cell in the body- Nodal, Extranodal, Cutaneous and Leukemic. Most of the subtypes are rare and mainly 4 subtypes of PTCL- peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma (ALCL), Nasal NK/T-Cell Lymphoma and angioimmunoblastic T-cell lymphoma (AITL) accounts for about 75% of the PTCL cases.
PTCL accounts for less than 10% of all diagnosed Non-Hodgkin’s lymphoma cases in North America and Western Europe. Very limited number of studies is available for Peripheral T-Cell lymphoma in Europe as the indication is very rare and to conduct population based studies not much patients were available. In Japan, Peripheral T-Cell lymphoma contributes to about 7.5-8% of total NHL cases. Though the overall PTCL cases are not so high but Southern Japan seems to have more concentration of PTCL cases.
The incidence of PTCL accounts for a larger fraction of all non-Hodgkin lymphoma cases in Asia than in the United States or Europe and the incidence of PTCL subtypes among patients display pronounced global variation.
Diligent Market estimates a higher prevalence of Peripheral T-Cell Lymphoma (PTCL) in the United States EU5 as compared to Japan. There were approximately a total of 16.5 thousand incident Peripheral T-Cell Lymphoma (PTCL) cases in the 7 major markets in 2016.
Total Incident Peripheral T-Cell Lymphoma (PTCL) Cases in 7 Major Markets (2016)
Stage wise Incident Peripheral T-Cell Lymphoma (PTCL) Cases in 7 Major Markets (2016)
Key Findings –
With upcoming drugs and treatment therapies, PTCL screening has been proven to greatly reduce the mortality rates that have declined in many longstanding as well as newly economically developed countries. Diagnoses were initially based on morphology and basic clinical information (age, sex, biopsy site and major site of involvement).
Then, diagnoses were made after introduction of the immunophenotype. For this, both the interpretation of the site pathologist and immunostained slides were available for review. Market of PTCL is expected to witness a slower growth rate till mid-2020, Increase in the growth rate is expected in the later forecast years due to expected launch of PTCL pipeline drugs.
The US had the largest market share in 2016 of the 7 MM, followed by Japan and Germany. Spain had the lowest market share in 7MM in 2016.
The present available therapies for PTCL are low in efficacy and there is lack of standard of care for PTCL. There is only one approved drug apart from chemotherapies for PTCL so there is a need for new therapies. The pipeline therapies face a problem in clinical trials as the number of patients in rarer subtypes of PTCL are very few. There are treatment options for newly diagnosed PTCLs but there is an unmet need for the relapsed/refractory cases. With the limited number of patient pool and high cost of therapy of available treatment, there is a need for less expensive treatments.
Market Size of Peripheral T-Cell Lymphoma (PTCL) for 7 Major Markets